Indications
Treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC).
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Xegafri
- ATC code
- L01XE
- Therapeutic area
- Carcinoma, Non-Small-Cell Lung
- Marketing authorisation holder
- Clovis Oncology UK Ltd
- Status
- Application withdrawn
- EMA product number
- EMEA/H/C/004053
EMA designations
- Orphan medicine
- Yes
- Conditional approval
- No